



Alameda Alliance for Health

FORMULARY UPDATE

**Effective 07/22/2024, unless indicated
below under Committee Actions.**

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the June 11, 2024, meeting:

Therapeutic/Monograph Class Reviews	
<ul style="list-style-type: none">• Opioid Use Disorder Agents Class Review (with PA criteria)• Phosphate Binders Class Review (with PA criteria)• Benign Prostatic Hyperplasia (BPH) Class Review• Rezdifra monograph<ul style="list-style-type: none">• New MRG: Rezdifra	<ul style="list-style-type: none">• Contraceptives foams, devices Class Review• Gaucher Disease Class Review• Ridaura Monograph• Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists Class Review

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

Generic//Biosimilar Name & Strength/Dosage Form	Brand Name	Committee Actions
ereenumab-aooe Subcutaneous Soln Auto- Injector 70 MG/ML	Aimovig Solution Auto- Injector 70 MG/ML Subcutaneous	Update to Non-Formulary (NF)
ereenumab-aooe Subcutaneous Soln Auto- Injector 140 MG/ML	Aimovig Solution Auto- Injector 140 MG/ML Subcutaneous	Update to NF
rimegepant Sulfate Tablet Disintegrating 75 MG	Nurtec Tablet Dispersible 75 MG Oral	Update to NF
lasmiditan Succinate Tab 100 MG	Reyvow Tablet 100 MG Oral	Update to NF
lasmiditan Succinate Tab 50 MG	Reyvow Tablet 50 MG Oral	Update to NF
zavegepant HCL Nasal Solution 10 MG/ACT	Zavzpret Nasal Solution 10 MG/ACT	Add to formulary with Prior Authorization (PA)
entecavir Tablet 0.5 MG Oral	Baraclude Tablet 0.5 MG Oral	Add to formulary
entecavir Tablet 1 MG Oral	Baraclude Tablet 1 MG Oral	Add to formulary

PRIOR AUTHORIZATION GUIDELINE UPDATES	
Gonadotropin Releasing Hormone Antagonists	Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
Lupkynis	Fenofibrates
Rezdifra monograph New MRG: Rezdifra	Nutritional formulas, infant formulas (STC C5F C5C)
Lidocaine Patch	vigabatrin (Sabril)
Hepatitis C Medications	Sedative Hypnotics
Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention	Acute Migraine Treatments
Complement Inhibitors for the Treatment of Myasthenia Gravis Agents	Eohilia
Wegovy	Filsuvez

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)	
Opioid Use Disorder (OUD) Agents	Formulary, step therapy required *For drugs without specific criteria
Phosphate Binders	Non-formulary and prior authorization required oral liquid formulations
Radicava ORS (edaravone)	Filspari
Daybue (trofinetide)	Joenja
Skyclarys (omaveloxolone)	Potassium-removing agents
Cholinesterase Inhibitors	Epidiolex (cannabidiol)
febuxostat (Uloric)	Tiagabine (Gabitril)
Lamotrigine ER	Topiramate (Topamax) sprinkles
Levalbuterol (Xopenex/Xopenex HFA)	Short acting opioid containing products
Lipotropics	Hemlibra (emicizumab-kxwh)
Long acting opioids	Aptiom (eslicarbazepine)
Serotonin Receptor Agonists (Tryptans)	Alprazolam (Xanax)
Pregabalin (Lyrica and Lyrica CR)	Rectiv (nitroglycerin) ointment
Rufinamide (Banzel)	Diuretics
Radicava ORS (edaravone)	Sleep Disorder Therapy
Daybue (trofinetide)	Palforzia
Filspari	Skyclarys (omaveloxolone)
Joenja	Hepatitis B Drugs
Transthyretin-mediated Amyloidosis Agents	Adenosine Triphosphate-Citrate Lyase (ACL) inhibitors
Medications for Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy	Xolair for Asthma and Urticaria
Roflumilast (Daliresp)	Anti-Obesity Medications
Injectable Atypical Antipsychotic Medications	Hereditary Angioedema (HAE)

**For questions, please contact the Alliance's Pharmacy Services department at:
(510) 747-4541.**